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Involucrin is one of the precursor proteins of keratinocyte 
cornified envelope. Although the formation of the cornified 
envelope is induced by tumor-promoting phorbol esters. the 
effect of 12-0-tetradecanoylphorbol-13-acetate (TPA) on 
the involucrin gene expression remains unknown. We have 
isolated a 5'-upstream region of human involucrin gene and 
examined its TPA-dependent promoter activity. The involu-
crin upstream region with the untranslated first exon was 
connected to chloramphenicol acetyl transferase (CAT)-
invol ucrin promoter expression vector (INV -CA T) and was 
transfected into fetal rat keratinizing epidermal (FRSK) cells. 
The INV -CAT - transfected FRSK cells showed consider-
able CAT activity that was significantly augmented by the 
treatment of cells with TPA. FRSK cells that were trans-
fected with a reversely oriented 5' -upstream sequence re-
vealed little CAT activity and did not respond to TPA. The 
effect of TPA was significantly inhibited by the protein ki-
nase C inhibitor 1-(5-isoquinoline-sulfonyl)-2-methyl pi-
T he cornified envelope is a highly insoluble sUb.c.eJlUlar . structure that is formed beneath the plasma mem-brane during terminal keratinocyte differentiation [1-4]. Among the precursors of human cornified en-velope is involucrin [2- 6]. which serves as a substrate 
for transglutaminase, a cross-linking enzyme [7 - 10]. Human invo-
lucrin gene has been cloned by Eckert and Green [11]. It contains a 
5' exon of 43 bp and a 3' exon of 2107 bp that are separated by an 
intron of 1188 bp. The coding region in the second exon contains a 
central portion with highly homo logous 39 repeats of a 30-base (10 
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Abbreviations: 
CAT: chloramphenicol acetyltransferase 
dCTP: deoxycytidine triphosphate 
FRSK cells: fetal rat keratinizing epidermal cells [27] 
GCR: glucocorticoid receptor 
H-7: 1-(S-isoquinoline-sulfonyl)-2-methyl piperazine dihydro-
chloride 
lNV -CAT: CAT -involucrin promoter expression vector 
JCRB: Japanese Cancer Research Bank 
OAG: 1-oleoyl-2-acetylglycerol 
PMA: phorbol myristate acetate 
TPA: 12-0-tetradecanoylphorbol-13-acetate 
TRE: TPA response element 
perazine dihydrochloride (H-7). Other protein kinase C 
activators (1-oleoyl-2-acetylglycerol and mezerein) also in-
duced the INV-CAT promoter activity, whereas 4-0-
methyl phorbol myristate acetate, a very weak protein kinase 
C activator, had only a slight effect. Analysis of the nucleo-
tide sequence of the 5' -upstream region detected several 
5' -TGANT~A-3' sequences that are highly conserved TPA-
resyonse elements (TRE). Cotransfection of both c-jurz and 
c-Jos expression vectors with the INV -CAT vector into ' 
FRSK cells resulted in increased CAT activity. Cotransfec-
tion of either the C-jUI1 or c-fos vector singly with the 
INV -CAT vector into FRSK cells had negligible effects. 
Dexamethasone significantly inhibited the TPA-induced 
promoter activity in the INV -CAT - transfected FRSK cells. 
These results indicate that involucrin gene expression is posi-
tively controlled by TPA through the activation of the pro-
tein kinase C/TRE system. J Il1vest Dermatol 100:10-15, 
1993 
amino acid) sequence. Sequence analysis suggests a recent evolu-
tionary origin of this central portion of the gene [11]; this was 
therefore termed the modem segment. Although several immunologic 
studies failed to detect involucrin in keratinocytes of subprimates 
[12]. this does not mean that subprimates do not contain the protein 
analogous to involucrin. because anti-involucril1 antibodies are usu-
ally directed against the modern segment [13] . Keratinocytes in 
subprimates also form cornified envelope at the terminal differen-
tiation stage. and "involucrin-like" proteins have been described in 
subprimates as well [13.14]. 
The phorbol ester tumor promoter 12-0-tetradecanoyl-phorbol-
13-acetate (TPA) induces a variety of changes in cell metabolism. 
morphology, and growth by directly affecting the activiry of pro-
tein kinase C [15]. Among these processes is the transcriptional 
activation of viral and cellular genes (see [16]). Analysis of the pro-
moter regions of these genes led to the identification of the cis-act-
ing TPA response element (TRE) 5'-TGANT~A-3' [16-18]. 
which serves as a binding site for the transcription factor AP-1, 
AP-1 is a complex consisting of several polypeptides, the most im-
portant of which are Fos and Jun. the products of the c-jull and C-J05 
proto-oncogenes, respectively. It is assumed that Fos/Jun hetero-
dimer affects TRE, resulting in the activation of TPA-responsive 
genes [16-19]. 
TPA. induces termina l differentiation of keratinocytes [20.21]. 
where 111volucnn has been suggested to be a good differentiation 
marker [22.23]., The effect of TPA on involucrin gene expression. 
however, rema1l1s unknown at present. Sequence analysis of the 
involucrin gene. which was reported by Eckert and Green [11]. 
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Figure 1. Restriction map of human genomic involucrin.The lo~ation of 
the individual exons 1S shown as a sol.d box. Non-coding reglOns are 
depicted as a solid lille. The BamHl and HindllI fragments were derived 
from Hl-l and HI-2 clones, respectively. The restriction sites are indicated 
as folloWS: BamHl (B), HindlII (H), Pst! (P), Scal (S), and Xbal (X). 
suggest~ the pr~sence of TRE in the 5' -upstream region of the 
human ll1volucnn gene. 
In the present study, we have subcloned a 5'-upstream region 
of the involucrin gene from the human genomic library. This 
was connected to a chloramphenicol acetyl transferase (CAT)-
involucrin promoter expression vector (INV-CAT) that was trans-
fected into fetal rat keratinizing epidermal (FRSK) cells, which 
initially do not express involucrin. Using the INV-CAT-
transfected FRSK cells, we investigated the possible promoter activ-
ity of INV-C~ T indu.ced by TP~. The expression of involucrin in 
various non-l11volucnn-expressll1g cells has been well demon-
strated by Rorke and Eckert [24] using an SV40 promoter-depen-
dent involucrin gene vector. 
MATERIALS AND METHODS 
Isolation and Characterization of Human Genomic Clones 
A human genomic DNA library constructed in EMlIL3 was obtained 
from The Japanese Cancer Research Bank (JCRB). This library was 
screened with 650-bp eDNA corresponding to human involucrin 
gene [11]. The eDNA (pI2) was a generous gift from Professor H. 
Green (Department of Cellular and Molecular Physiology, Harvard 
Medical School). Among 5 X 105 recombinant clones, HI-l and 
HI-2 clones, which contain the 14- and 13-kb insert, respectively, 
were strongly hybridized with the probe. A 6.6-kb BamHI frag-
ment of Hl-l clone and a 6.3-kb HindlII fragment of HI-2 clone 
were subcloned into pBR322 plasmids, and the restriction map 
study was performed (Fig 1). These two subclones turned out to be 
very close each other. An Seal-digested fragment that contained a 
substantial 5' -upstream promoter region with the untranslated first 
exon [11] (Fig 1) was isolated from the subclones and inserted into 
the Smal site of the pGEM3Zf(+) vector. Nucleotide sequencing 
was performed using the dideoxynucleotide chain termination 
method [25], utilizing T7 and SP6 primers. 
plasmid Constructs The Seal-digested fragment from genomic 
involucrin gene (Fig 1) was inserted into the Xbal site of promoter-
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Figure 2. Effect of TP A on INV -CAT - transfected FRSK cells . FRSK cells 
were transfected with forward- and reverse-constructed INV -CAT vector 
(5 J.Lg/I05 cells) and then incubated with (+) or without (-) TPA (10 
ngjrnl) for 24 h . DNA(-) represents the mock transfection. Data are the 
representative of three independent experimental series with duplicate 
assays. 
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less O-CAT plasmid that had been blunt-ended by Klenow fragment 
(INV-CAT). The fragment contained the TAT A box as well as the 
untranslated first exon of the involucrin gene [11]. The c-jul'! and 
c-fos expression vectors were generous gifts from Dr. M. Karin 
(Department of Pharmacology, Uiliversity of California) [26)' 
Cell Culture FRSK cells, a cultured cell line of fetal rat epider-
mal keratinocytes [27], were obtained from the JCRB, Cell Foun-
dation for Promotion of Cancel.' Research. SV 40-transformed 
human keratinocytes [28] were a generous gift from Dr. M . L. 
Steinberg (Department of Chemistry, City College of the City 
University of New York). Th.ese cells were cultured in Dulbecco's 
modified Eagle's medium supplemented with 5% fetal calf serum, 
100 U/ml penicillin, and 100 ,ug/ml streptomycin at 37°C in 5% 
CO2 in air. 
Transfection and CAT Assay Transfection of plasmid DNA 
into FRSK cells was performed using the liposome method with 
lipofectin [29] . Typically, 5 ,ug of reporter plasmid and 2.ug of 
p-galactosidase expression plasmid were transfected into 105 cells. 
The p-galactosidase plasmid Was a generous gift from Professor T. 
Watanabe (Medical Institute ofBioregulation, Kyushu University, 
Japan) and was used as the internal standard to normalize each 
transfection efficacy [30]. Twenty-four hours after transfection, 
TPA (10 ngjml), 1-0Ieoyl-2-acetylglycerol (OAG) (100.ug/ml) , 
mezerein (1 ,uM.), and various chemicals were added to the incuba-
tion medium. After 48 h, cells were collected and CAT assays were 
performed according to the method of Neuman et al [31]. CAT 
activity was corrected for the p-galactosidase activity of the control 
(O-CAT transfected) FRSK cells in each experimental series. Exper-
iments were repeated at least three times throughout the present 
study. 
Northern Blot Analysis Total RNA was extracted by the ce-
sium guanidine method [30]. Poly(A)+ RNA was purified on an 
oligo-dT cellulose column. The poly(At RNA (5 Ilg) was electro-
phoresed in 1 % agarose gel and transferr~d to a nylon filter. The 
human involucrin cDNA was labeled With [a-32P]deoxycytidine 
triphosphate (dCTP) (3000 Ci/mmol) by random primer method. 
Hybridization was performed as described previously [32]. 
Materials Dulbecco's modified Ea~le'~ medium was purchased 
from Gibco (Grand Island, NY) . PemCIJlm and streptomycin were 
obtained from M.A. Bioproducts (Walkersville, MD). [a-32P)dCTP 
and [3H]acetyl coenzyme A were obtained from Amersham ('Tokyo, 
Japan). O-CAT and pGEM3Zf(+) plasmids were purchased from 
Promega (Madison, WI). Lipofectin was obtained from BRL (Be-
thesda, MD) . TPA, 4-0-methyl phorbol myristate acetate (4-0-
methyl PMA), mezerein, alld dexamethasone were purchased from 
Sigma (St. Louis, MO). OAG was the product of Calbiochem (La 
Jolla, CA). H-7 was purchased from Seikagaku Kogyo Co. (Tokyo, 
Japan). All other chemicals were obtained from Nakarai Chemicals 
Ltd. (Kyoto, Japan). 
RESULTS 
The involucrin promoter expression vector (INV -CAT), con-
structed as described in Materials and Methods, was introduced into 
FRSK cells by using the Ii pofectin-mediated transfection method 
[29]. As a negati,:,e control, O-CAT vector, the prornoterless paren-
tal vector, was ll1troduced.. The INV-CAT plasmid, which was 
forward-oriented inserted, revealed a significant CAT gene e:xpres-
sion (Fig 2). Reverse-orien.ted - inserted plasmid was inactive. The 
promoter activity was significantly augmented by the addition of 
TPA (10 ngjml) t? the incubation medium (Fig 2). Although the 
mag11ltude of the 1~crease varied among each experimental series 
(1.5 - 3 tl111es), the mcrease was consistently observed in the INV-
CAT-transfected cells by the TPA treatment. 
The protein kinase C inhibitor B-7 [33] significantly inhibited 
the effect ofTPA on INV-CAT expression (Fig 3). The addition of 
H-7 singly to the incubation medium had no effect on the promoter 
activity (data not shown). 
The effect ofTPA was tnimicked by OAG, a membrane-perme-
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Figure 3. Effect of the protein kinase C inhibitor H-7 on TPA-induced 
INV-CAT expression_ Following transfection, FRSK cells were incubated 
with TPA (10 ng/ml) or H-7 (100 IlM), or both, for 24 h. Data are 
representative of three independent experimental series with duplicate 
assays. 
able synthetic diacylglycerol [34]. and by the non-phorbol protein 
kinase C activator mezerein [35] (Fig 4). 4-0-Methyl PMA, a very 
weak protein kinase C activator [36], produced much less effect on 
the promoter activity. 
S~quence analysis of the 5' upstream promoter region detected 
two complete TRE (5'-TGAGTCA-3' and 5'-TGACTAA-3') se-
quences and one TRE-like (5'-TGACTCT-3') sequence in the up-
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Figure 4 . Effect of various protein kinase C activators. FRSK ceUs were 
incubated with OAG (100 Ilg/ml), mezerein (1 pM), or 4-0-methyl PMA 
(200 ng/ml) for 24 h following transfection. Data are representative of 
three independent experimental series. 
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Figure S. Sequence of the 5' -upstream region of human involucrin gene. 
Thill I/llderscoring indicates the TAT A box; thick ulldersco rillg indicates the 
transcription start of the first exon [11] . The three sequences enclosed in 
boxes indicate TRE (and TRE-like) regions. 
It is known that TRE is recognized either by the c-Jun/c-Fos 
heterodimer or by the c-Jun/c-Jun homodimer that activates TPA-
dependent gene expression in various cell systems [16 - 19] . Co-
transfection of INV -CAT vector with both c-jlm and c-Jos expres-
sion vectors into FRSK cells resulted in the increased promoter 
activity similar to the extent ofTPA (Fig 6) . In contrast, cotransfec-
tion of either the c-jun or c-Jos vector singly with the INV -CAT 
vector had no effect on the promoter activity. 
Recent evidence suggests the interaction between TP A and glu-
cocorticoid effects at the transactivation level of each responsive 
element [26,37,38] . Dexamethasone significantly inh ibited the ef-
fect of TP A 011 INV -CA T - transfected FRSK cells (Fig 7). 






























Figure 6. Effects of cotransfections of INV-CAT vector with c-jull and/ 
or c-fos, expression vectors. The lNV-CAT vector (5 Ilg/10s cells) was 
transfected to FRSK cells in the presence (+) or absence (-) of C-jllll (2 
IIg/IOs cells) and c-Ios (2Ilg/10s cells). For TPA experiments, INV-CAT-
transfected cells were incubated with TPA (10 ng/ml) for 24 h. Data are 
the representative of three independent experimental series. 
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Figure 7. Effects of dexamethasone on INV-CAT- transfected FRSK 
cells. Following transfection, FRSK cells were incubated with IPA (10 
ng/ ml) and or dexamethasone (DEX)(l pM) for 24 h. Data are representa-
tive of three independent experimental series. 
K eratinocytes of subprimate species, including FRSK cells, do not 
express involucrin. To confirm the effect ofTPA on the involucrin 
expression of keratinocytes , SV 40-transformed human keratino-
cy tes were used . . Northern blot analysis reveale~ increased involu-
crin mRNA, which was observed by 3 h foll ow1l1g the TPA treat-
ment and persisted up to 24 h (Fig 8). The TPA-induced involucrin 
expression was also confirmed by flow-cytometric ana lysis using 
anti-involucrin antibody. The TPA-treated SV40-transform ed 
human keratinocytes expressed twice as much involucrin immuno-
fluorescence by 24 h (data not shown). Because the transfection 
effi cacy of the INV-CAT vector into SV40-transformed human 
keratinocytes was much less than that into FRSK cells, we could not 
obtain the TPA-stimulated INV -CAT activity by using SV 40-
transformed human keratinocytes. 
DISCUSSION 
Our results indicate that the 5' -upstream region of human involu-
crin ge ne contains a functional promoter activity that is signifi-
cantly activated by TPA (Fig 2) . The reverse-oriented 5'-upstream 
sequence had no promoter ac tivity nor was it induced by TPA. 
Although the induction of involucrin is not confirmed in FRSK 
cells (which do not have the " involucrin modern segment" [1 2-
14)) , TPA-dependent involucrin expression was demonstrated in 
SV40-transformed human keratinocytes (Fig 8). The SV40-trans-
formed human keratinocytes unfortunately showed much less 
transfection effi cacy than the FRSK cells. 
The effect of TPA is assumed to be mediated through protein 
kinase C [15,1 6,36] . Consistent with this, the TPA-dependent in-
vo lucrin promoter activity was mimicked by other protein kinase C 
activators (OAG and mezerein). On the other hand, 4-0-methyl 
PMA, a very weak protein kinase C activator, had on ly a slight effect 
(Fig 4) . Further: the eff~ct .o~ TPA on the i~1Volucrin ~rom~ter 
activity W:lS sigl1lfica ntly II1hlblted by the protell1 kll1:lse C II1I11bltor 
B-7 (Fig 3). 
Recent evidence suggests that TPA reveals its transcriptional 
control through the Jun/ Fos heterodimer, which activates cis-act-
ing AP-l binding site(s), termed TRE [17 - 19]. TPA induces both 
c-Jun and c-Fos expression [39 ,40]. It also decreases phosphoryl-
ation of c-Jun at sites that negatively regu late its DNA bindin g 
activity [16] . Our sequence analysis detected two TRE sequences 
and one TRE-like sequence in the 5'-upstream region (Fig 5) . 
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Figure 8. Effect of IPA on involucrin (INV) mRNA levels of SV40-
rransformed human keratinocytes. SV40-transformed human keratino-
cytes were treated with IPA (10 ng/ml) for the indica ted time. Poly(At 
RNA (2pg) was loaded on each lane. 
Although we cannot distinguish the exact promoter site(s) at pre-
sent, a study is in progress in our laboratory to locate the putative 
AP-l binding site(s) using the mutated 5' -upstream involucrin pro-
n10ter. 
T ranscriptional interference between c-Jun and glucocorticoid 
teceptor (GCR) was described, which s~ggests that GCR is a nega-
tive regulator of AP-l [26,37,38]. ConsIStent wlth this, dexametha-
sone significantly inhibited the TPA-induced involucrin promoter 
activity (Fig 7). Because of the multifunctional nature of the gluco-
corticoid and protein kinase C re gulation, it is tempting to speculate 
that a similar mechanism is operative for other interfe rence systems: 
g lucocorticoids have been known to antagonize various effects of 
TPA, including those on keratinocytes [26 ,37,38,41] . 
Although involucrin is not the major component of normal kerat-
inocyte cornified envelope [4 ,42,43], it could be a case in pathologic 
conditions such as psorias is. It is interesting to note that the prema-
ture expression of involucrin is observed in the psoriatic epidem1is 
[22,44,45] and that the composition of the psoriatic cornified enve-
lope is very similar to that of involucrin [46]. Protein kinase C 
activation has been suggested to occur in the psoriatic epidermis 
[47]; the apparent decrease in protein kinase C activiry is assumed to 
refl ect the downregulated status of the enzyme followin g its activa-
tion [47,48]. 
It has been known that : pidermal transglutaminase is induced by 
TPA [49,50] . Our results IIldlcate that one of the substrates of this 
enzyme, involucrin, is also under the c011trol ofTPA. Thus, TPA 
affects keratinocyte differentiation at the transcriptional level of 
both tra nsglutamina~e and il.1Volucrin. The effects ofTPA (besides 
inducing termmal differentiation for a committed population of 
kera tinocytes [20]) modulate keratinocyte maturation. This could 
be rel ated to an alternative pathway of keratiniza tion in the wou nd-
repairing process [51] , which apparently shares many features with 
the psoriatic hyperproliferative epidermis. 
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